TABLE 1.
Sample Name | CER | FFAs |
LPP-CH2 | EOS/NS | C16/C18/C20/C22/C24 |
LPP-dNS | EOS/d47-NS | C16/C18/C20/C22/C24 |
LPP-dFFAs | EOS/NS | d31-C16/d35-C18/d39-C20/d43-C22/d47-C24 |
LPP-dNS/dC24 | EOS/d47-NS | C16:0/C18:0/C20:0/C22:0/d47-C24 |
LPP-dNS/dFFAs | EOS/d47-NS | d31-C16/d35-C18/d39-C20/d43-C22/d47-C24 |
dFFA | — | d31-C16/d35-C18/d39-C20/d43-C22/d47-C24 |
LB-dNS/dC24 (6:4) | d47-NS | d47-C24 |
LB-dNS/dFFA (3:5) | d47-NS | d31-C16/d35-C18/d39-C20/d43-C22/d47-C24 |
The deuterated labeled lipids (d) are highlighted in bold. All LPP samples additionally contained CHOL in an equal molar ratio to CERs and FFAs, while the lipid ratios in the LB samples are expressed in the table.